Hospital
DLP Rutherford Regional Health System, LLC
DLP Rutherford Regional Health System, LLC was paid $14.37M by Medicaid between Jan 2018 and Dec 2024, across 125 billing codes. Its largest line is 99285, emergency room visit (most serious) — 20% of everything it billed.
33Billing provider infoDLP RUTHERFORD REGIONAL HEALTH SYSTEM, LLC
RUTHERFORDTON, NC 28139
RUTHERFORDTON, NC 28139
33aNPI1245321181assigned 09/27/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$14.37M
24GClaims423,987
24DCodes billed125
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#39 of 92
Median peer was paid$11.47M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 69,584 | $1.63M | |
| 2019 | 62,430 | $1.34M | |
| 2020 | 47,676 | $1.06M | |
| 2021 | 53,472 | $1.63M | |
| 2022 | 59,823 | $2.69M | |
| 2023 | 65,720 | $3.01M | |
| 2024incomplete | 65,282 | $3.01M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 20% | 17,080 | 14,557 | $2.87M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 28,753 | 25,143 | $2.72M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 20,447 | 17,848 | $2.50M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.5% | 1,416 | 1,248 | $934K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 3.5% | 3,305 | 2,821 | $507K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.4% | 11,334 | 9,709 | $350K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.4% | 2,383 | 2,024 | $348K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.2% | 6,819 | 4,913 | $318K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 3,811 | 3,380 | $231K |
| 80053 | Comprehensive metabolic panel | 1.6% | 28,907 | 24,412 | $230K |
| 71045 | Radiologic examination, chest; single view | 1.5% | 6,220 | 5,196 | $219K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.4% | 2,740 | 2,243 | $204K |
113 more codes
| J7030 | Infusion, normal saline solution , 1000 cc | 1.4% | 13,820 | $201K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 28,088 | $191K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 2,312 | $179K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.2% | 11,382 | $170K |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 3,576 | $146K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.0% | 14,610 | $146K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,102 | $129K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 265 | $127K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 8,088 | $100K |
| 87088 | <1% | 11,723 | $91K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,743 | $90K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 777 | $83K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,806 | $82K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,404 | $81K |
| 87070 | <1% | 6,650 | $78K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,367 | $71K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,291 | $71K |
| 83690 | <1% | 8,359 | $54K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,896 | $53K |
| A9270 | Non-covered item or service | <1% | 52,668 | $51K |
| 81025 | <1% | 6,862 | $49K | |
| 84484 | <1% | 6,665 | $49K | |
| 88312 | <1% | 662 | $43K | |
| 81001 | <1% | 13,874 | $41K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 711 | $33K |
| 59025 | Fetal non-stress test | <1% | 742 | $32K |
| 83880 | <1% | 1,142 | $31K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 189 | $30K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 853 | $30K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,059 | $26K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 841 | $23K |
| J3490 | Unclassified drugs | <1% | 4,912 | $23K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,589 | $21K |
| 85730 | <1% | 4,422 | $20K | |
| 83735 | <1% | 3,406 | $19K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 708 | $19K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 459 | $19K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,061 | $17K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 835 | $17K |
| 85610 | <1% | 5,484 | $16K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,063 | $15K |
| 83605 | <1% | 1,382 | $15K | |
| 80061 | Lipid panel | <1% | 756 | $14K |
| 81003 | <1% | 5,635 | $12K | |
| 87186 | <1% | 1,317 | $12K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,687 | $10K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,053 | $10K |
| 88304 | <1% | 236 | $9K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,402 | $7K |
| 87077 | <1% | 747 | $6K | |
| 87040 | <1% | 594 | $6K | |
| 82550 | <1% | 859 | $5K | |
| 86140 | <1% | 1,010 | $5K | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 202 | $5K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,081 | $5K |
| 87420 | <1% | 321 | $5K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 117 | $4K |
| 85027 | <1% | 576 | $4K | |
| 73630 | <1% | 72 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,310 | $3K |
| 73610 | <1% | 56 | $3K | |
| 85380 | <1% | 322 | $3K | |
| G0378 | Hospital observation service, per hour | <1% | 12 | $2K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 14 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 650 | $2K |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 29 | $2K |
| 86803 | <1% | 78 | $2K | |
| 84145 | <1% | 80 | $1K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 12 | $1K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 192 | $1K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 18 | $1K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 347 | $1K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 81 | $1K |
| 73110 | <1% | 12 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 116 | $1K |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 42 | $1K |
| 88342 | <1% | 13 | $1K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 30 | $1K |
| 73564 | <1% | 31 | $1K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 16 | $797.96 |
| 80320 | <1% | 91 | $699.34 | |
| 73130 | <1% | 15 | $667.94 | |
| 73030 | <1% | 16 | $620.97 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 211 | $575.83 |
| 84100 | <1% | 168 | $573.63 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 47 | $478.04 |
| 87081 | <1% | 139 | $449.69 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 37 | $411.49 |
| J7626 | Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg | <1% | 43 | $402.26 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 411 | $347.19 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 44 | $318.54 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 32 | $297.47 |
| 86703 | <1% | 15 | $283.85 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 46 | $254.04 |
| 87340 | <1% | 14 | $207.72 | |
| 83655 | <1% | 13 | $196.04 | |
| 82800 | <1% | 27 | $179.73 | |
| 84702 | <1% | 13 | $173.36 | |
| 82728 | <1% | 13 | $149.89 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 63 | $143.15 |
| 80329 | <1% | 27 | $138.18 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 14 | $115.83 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 69 | $108.75 |
| 86592 | <1% | 18 | $103.10 | |
| 82962 | <1% | 51 | $102.89 | |
| 83615 | <1% | 13 | $58.61 | |
| 82009 | <1% | 13 | $56.33 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 46 | $51.39 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 14 | $44.50 |
| 85018 | <1% | 13 | $38.35 | |
| 85014 | <1% | 13 | $38.35 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 34 | $13.14 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 15 | $8.87 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.